Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, Multi-center, Extension Study to Further Evaluate the Safety, Pharmacodynamics and Pharmacokinetics of Ozanimod and Active Metabolites in Healthy Adult Subjects

NCT03665610 is registered in ClinicalTrials.gov with Celgene as lead sponsor.

NCT NCT03665610
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03665610 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, Multi-center, Extension Study to Further Evaluate the Safety, Pharmacodynamics and Pharmacokinetics of Ozanimod and Active Metabolites in Healthy Adult Subjects
Lead sponsor
Celgene
Phase
Observational
Overall status
Completed
Start date
September 10, 2018
Completion date
January 10, 2019
Enrollment
212 (actual)
Sites
2

Conditions

As the registry lists them; a condition with its own page is linked.

healthy volunteers